Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New NPY Y5 receptor antagonists in early development at Schering-Plough

Feb. 20, 2004

Enrollment under way in ORIGIN trial

Feb. 20, 2004

Arexis acquires BSSL project from AstraZeneca

Feb. 20, 2004

Dow to produce NLC-001 in plant-based system

Feb. 19, 2004

Roche presents novel NPY antagonists with potential in obesity and other disorders

Feb. 19, 2004

Novel PPARdelta agonists under study at Bayer

Feb. 19, 2004

Two series of MCH1 antagonists and their use reported by Synaptic researchers

Feb. 19, 2004

New orexin antagonists for obesity and sleep disorders in early development at Actelion

Feb. 18, 2004

AstraZeneca claims MCH-1R antagonists with potential as antiobesity agents

Feb. 18, 2004

Improved postprandial glycemia found with HIM2 in type 1 diabetes

Feb. 18, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 27, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
Researchers identify innate immune barrier against melanoma
BioWorld
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
In the clinic for May 26, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: 858, A2 Biotherapeutics, AC Immune, Agendia, Agenus, Aktis, Ascentage,...
Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers
BioWorld Science
Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...